A REVIEW ARTICLE TO DEVELOP SUSTAIN RELEASE RIVAROXABAN FORMULATION

Journal Title: Journal of Atoms and Molecules - Year 2012, Vol 2, Issue 2

Abstract

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto.[1] In the United States, it is marketed by Janssen Pharmaceutical.[2] It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.

Authors and Affiliations

K. Sapna, G. Sudhakar, Dr. R. Santosh Kumar

Keywords

Related Articles

COLLABORATIVE APPLICATIONS OF OVERLAY NETWORKS: A PERSPECTIVE.

The main objective of this research is to minimize delay in collaborative applications by setting tight bounds. Examples of collaborative applications include video-conferencing, distributed database replication and onli...

ANTIBIOGRAM OF TRADITIONAL MEDICINAL PLANT CALOTROPSIS GIGANTEA EXTRACTS AGAINST STAPHYLOCOCCUS AUREUS AND VIBRIO CHOLERAE.

The increasing incidences of microbial infection and gradual rise in resistance in microbes and the available antibiotics had high-lightened the need to find more alternative antifungal and antimicrobial agents from othe...

TARGETING EFFICIENCY EVALUATION OF FLUOROURACIL IN PLGA MICROSPHERES CONJUGATED WITH HUMAN MONOCLONAL ANTIBODIES

In the advent of producing an effective tumour targeting drug system, Poly lactic acid-co-glycolic acid microspheres were formulated using Double (multiple) emulsion technique with and without human Ig G. The ideal ratio...

RP BT GENE AND BT PROTEIN STUDIES IN TULASI COTTON HYBRIDES BY PCR AMPLIFICATION

Cotton, the most prevalent fiber used in the clothing today, often referred as the White Gold. It contributing up to 75% of total raw material needs of textile industry. But, cotton crop is highly susceptible to insects;...

SYNTHETIC APPROACH TOWARDS PYRIMIDO [4, 5-B] QUINOLINE WITH 2-SUBSTITUTED DERIVATIVES AND STUDY OF ANTIMICROBIAL ACTIVITY

2-Amino-8-nitropyrimido[4,5-b]quinoline (1) and ethyl 2-cyano-3,3-bis(methylthio)acrylate (2) were refluxed in N,N-dimethyl formamide (DMF) in presence of catalytic amount of anhydrous potassium carbonate to afforded 3-c...

Download PDF file
  • EP ID EP367617
  • DOI -
  • Views 71
  • Downloads 0

How To Cite

K. Sapna, G. Sudhakar, Dr. R. Santosh Kumar (2012). A REVIEW ARTICLE TO DEVELOP SUSTAIN RELEASE RIVAROXABAN FORMULATION. Journal of Atoms and Molecules, 2(2), 14-16. https://europub.co.uk/articles/-A-367617